Development of an Inactivated Vaccine against SARS CoV-2
SARS COV-2에 대한 불활성 백신의 개발
Article
[키워드] Adenovirus
Aluminium
aluminium hydroxide
animal models
approved
AstraZeneca
BALB/c mice
breath
candidate
candidate vaccine
changed
clinical development
clinical trial
Complete
COVID-19
COVID-19 pandemic
COVID-19 vaccine
develop
development
Device
distribution
Efficacy
elicited
Emergency use
ERUCoV-VAC
ferrets
hACE2
HCoV
help
human clinical trial
human clinical trials
hydroxide
immunogenic
immunogenicity
inactivated
Inactivated vaccine
include
Johnson & Johnson
K18-hACE2
Medical devices
Medicine
mice
Moderna
mRNA
name
outbreak
Pfizer-BioNTech
Phase 3
phase 3 clinical trial
progression
Protective
respiratory
safety evaluation
SARS CoV-2
SARS-CoV-2
SARS-CoV-2 vaccine
Sinopharm
Sinovac
Spread
strain
strong immune response
the vaccine
the WHO
transgenic mice
TURKOVAC
university
upper respiratory tract
upper respiratory tracts
Vaccine
vaccine candidate
Vaccines
Viral
viral clearance rate
Viral vector
viral vectors
was used
[DOI] 10.3390/vaccines9111266 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/vaccines9111266 PMC 바로가기 [Article Type] Article